GlassScriptPhysician profile
Brian K Greenberg
NPI 1821023201
$45,200.11
in general payments reported to CMS, 2019-2025
20 companies · $518 in 2025
The $518 reported for 2025 was more than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,120 · 2020: $8,901 · 2021: $3,351 · 2022: $16K · 2023: $7,660 · 2024: $3,531 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,752.43 |
| Food and Beverage | $956.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Henry Schein, INC. | $43,463.16 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $340.26 | 2019-2024 | Fasenra |
| Pfizer INC. | $261.55 | 2019-2025 | |
| Amgen INC. | $192.72 | 2022-2025 | Tezspire |
| Sanofi Pasteur INC. | $135.10 | 2025 | |
| Novartis Pharmaceuticals Corporation | $123.75 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $113.44 | 2019-2024 | Gardasil 9, M-M-R II, Proquad |
| Circassia INC. | $97.00 | 2019-2022 | |
| Glaxosmithkline, LLC. | $58.40 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Ars Pharmaceuticals Operations, INC. | $55.90 | 2025 | Neffy |
| Abbott Laboratories | $51.53 | 2025 | Id Now Instrument |
| Phadia US INC. | $49.45 | 2021-2024 | Immunocap |
| Jubilant Hollisterstier LLC | $44.71 | 2023 | |
| Alk-Abello, INC | $41.78 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $39.19 | 2025 | Orladeyo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $34.86 | 2023 | Takhzyro |
| Cranial Technologies, INC | $32.00 | 2022-2025 | Doc Band |
| Azurity Pharmaceuticals, INC. | $24.02 | 2025 | Alvesco |
| Regeneron Healthcare Solutions, INC. | $23.41 | 2023 | Dupixent |
| Biofire Diagnostics, LLC | $17.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Greenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.